Prosecution Insights
Last updated: April 19, 2026

Examiner: CHENG, KAREN

Tech Center 1600 • Art Units: 1621 1622 1623 1626

This examiner grants 76% of resolved cases

Performance Statistics

76.4%
Allow Rate
+16.4% vs TC avg
711
Total Applications
+27.9%
Interview Lift
823
Avg Prosecution Days
Based on 677 resolved cases, 2023–2026

Rejection Statute Breakdown

1.0%
§101 Eligibility
21.5%
§102 Novelty
27.4%
§103 Obviousness
30.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18282874 METHOD FOR PREPARING ENANTIOMERICALLY ENRICHED 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-HYDROXY-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE BY HYDROGENATION OF THE 2-OXO DERIVATIVE IN THE PRESENCE OF A CHIRAL TRANSITION METAL CATALYST Non-Final OA BASF SE
18008648 PREPARATION METHOD OF ACRYLONITRILE DIMER Final Rejection LG CHEM, LTD.
18266688 INHIBITORS OF NEF DOWNMODULATION Non-Final OA THE REGENTS OF THE UNIVERSITY OF MICHIGAN
18026877 METHOD FOR PRODUCING SULFONATE COMPOSITION Non-Final OA KAO CORPORATION
17620103 FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE Final Rejection UNIVERSITY HEALTH NETWORK
17768152 LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME Final Rejection DUKE UNIVERSITY
17791659 AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE Final Rejection Uniwersytet Jagiellonski
17635631 ARYL AND PYRIDYL AMIDE PESTICIDES AND COMPOSITIONS THEREOF Final Rejection University of Florida Research Foundation, Incorporated
17774723 Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same Non-Final OA UNIVERSITY OF HAWAII
17772660 Continuous synthesis method for ethoxymethylenemalononitrile Final Rejection ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.
17279518 NOVEL USES Final Rejection INTRA-CELLULAR THERAPIES, INC.
17610303 PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF Non-Final OA Daewoong Pharmaceutical Co., Ltd.
18564763 FACTOR XIIA INHIBITORS Non-Final OA Lunac Therapeutics Ltd
18476926 LARGE SCALE SYNTHESIS OF CANNABINOL Non-Final OA Colorado Chromatograpy, LLC
18276831 A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF Non-Final OA GBR LABORATORIES PRIVATE LIMITED
17616586 BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX Non-Final OA UNIVERSITY OF MARYLAND, BALTIMORE
18268312 2-CYANOACRYLATE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Non-Final OA JIANGSU PESTICIDE RESEARCH INSTITUTE CO., LTD.
18210783 BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF Non-Final OA BORAH, INC.
18304815 TRIAZOLONE COMPOUNDS AND USES THEREOF Final Rejection Tempest Therapeutics, Inc.
18044613 PHOSPHATIDYLALKANOL HOMOLOGUES HAVING LABELLED MOIETIES Non-Final OA CHIRON AS
18042907 INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB Non-Final OA Universität Des Saarlandes
18020833 MRGPRX4 Agonists and Antagonists Non-Final OA Rheinische-Friedrich-Wilhelms-Universität Bonn
18012364 BRANCHED LIPID COMPOUDS Non-Final OA ENA Respiratory Pty Ltd
17639013 TREATMENT OF OBESITY AND RELATED CONDITIONS Non-Final OA University of Greenwich
17906677 PROCESS FOR THE PREPARATION OF PROPOFOL Final Rejection FRESENIUS KABI ONCOLOGY LTD.
17841572 METHODS AND FORMULATIONS FOR CONTROLLING FLEA INFESTATIONS Final Rejection EctoGuard, LLC
17832678 METHODS OF MAKING CHOLIC ACID DERIVATIVES AND STARTING MATERIALS THEREFOR Non-Final OA Sandhill One, LLC
17770794 TREATMENT OF EPILEPTIC CONDITIONS WITH GABAA RECEPTOR MODULATORS Non-Final OA NEUROCYCLE THERAPEUTICS, INC.
17420756 HtrA Inhibitors and CagA Inhibitors and Use Thereof Non-Final OA PSOMAGEN INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month